Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients

Barta, Stefan K.; Xue, Xiaonan; Wang, Dan; Tamari, Roni; Lee, Jeannette; Mounier, Nicolas; Kaplan, Lawrence D.; Ribera, Josep‐Marǐa; Spina, Michele; Tirelli, Umberto; Ra, Weiss; Galicier, Lionel; Boué, François; Wilson, Wyndham H.; Wyen, Christoph; Oriol, Albert; Navarro, José Tomás; Dunleavy, Kieron; Little, Richard F.; Ratner, Lee; García, Olga; Morgades, Mireia; Remick, Scot C.; Noy, Ariela; Sparano, Joseph A.

doi:10.1182/blood-2013-04-498964

Cited by 165 publications

(150 citation statements)

References 43 publications

Supporting

Mentioning

131

Contrasting

Unclassified

Order By: Relevance

“…52,53 It is unclear, however, whether any patients with PBL were included in this analysis. Importantly, two prospective studies are evaluating the safety and efficacy of infusional EPOCH in patients with high-risk DLBCL, including PBL (NCT01092182 and CTSU-9177).…”

Section: Current Treatment Options and Emerging Therapiesmentioning

confidence: 99%

The biology and treatment of plasmablastic lymphoma

Castillo

Bibas

Miranda

2015

Blood

379

543

View full text Add to dashboard Cite

Plasmablastic lymphoma (PBL) is an aggressive lymphoma commonly associated with HIV infection. However, PBL can also be seen in patients with other immunodeficiencies as well as in immunocompetent individuals. Because of its distinct clinical and pathological features, such as lack of expression of CD20, plasmablastic morphology, and clinical course characterized by early relapses and subsequent chemotherapy resistance, PBL can represent a diagnostic and therapeutic challenge for pathologists and clinicians alike. Despite the recent advances in the therapy of HIV-associated and aggressive lymphomas, patients with PBL for the most part have poor outcomes. The objectives of this review are to summarize the current knowledge on the epidemiology, biology, clinical and pathological characteristics, differential diagnosis, therapy, prognostic factors, outcomes, and potential novel therapeutic approaches in patients with PBL and also to increase the awareness toward PBL in the medical community.

show abstract

Section: Current Treatment Options and Emerging Therapiesmentioning

confidence: 99%

The biology and treatment of plasmablastic lymphoma

Castillo

Bibas

Miranda

2015

Blood

379

543

View full text Add to dashboard Cite

show abstract

“…A detailed description of the search strategy has been previously reported 12 and is available in the Online Supplementary Appendix. We limited our dataset to only patients treated with rituximab-containing chemoimmunotherapy.…”

Section: Patients and Data Collectionmentioning

confidence: 99%

“…We created three risk groups similarly to the aaIPI: low (LR; score 0-6), intermediate (IR; score 7-10) and high risk (HR; score [11][12][13][14][15]. Distribution of these groups is described in Online Supplementary Table 3S.…”

Section: Comparison Between Arl-ipi and Aaipimentioning

confidence: 99%

A new prognostic score for AIDS-related lymphomas in the rituximab-era

et al. 2014

View full text Add to dashboard Cite

Methods Patients and data collectionWe performed a systematic review of the literature to identify prospectively conducted clinical trials that assessed therapeutic interventions for HIV-associated NHL. A detailed description of the search strategy has been previously reported 12 and is available in the Online Supplementary Appendix. We limited our dataset to only patients treated with rituximab-containing chemoimmunotherapy.

show abstract

“…A meta-analysis of NHL treatment in 1456 patients by Barta and colleagues concluded that rituximab is associated with a higher complete remission rate and improved progression-free survival (PFS). 19 In addition, infusional EPOCH (etoposide ϩ prednisone ϩ vincristine ϩ cyclophosphamide ϩ doxorubicin) was associated with better OS in the patients with DLBCL.…”

Section: Therapymentioning

confidence: 99%

HIV-associated non-Hodgkin lymphoma: viral origins and therapeutic options

Krishnan¹,

Zaia

2014

Hematology

View full text Add to dashboard Cite

HIV infection is associated with an increased risk of malignancy, especially B-cell lymphoid malignancies. Many of these lymphomas are further driven by concomitant infection with viruses such as Epstein-Barr virus or Human Herpesvirus 8, the latter being implicated in uncommon types of lymphomas seen in the setting of HIV-1 infection. Treatment outcomes have improved due to infusional chemotherapy, high-dose chemotherapy, and effective antiretroviral therapy. Successful functional cure of HIV-1 infection has been demonstrated with the use of allogeneic hematopoietic stem cell transplantation. This result spurred a change in the field of HIV-1 management so that, ultimately, the goals of therapy would shift from not only curing the underlying lymphoma, but also curing the HIV-1 infection. Treatment options will be discussed with an emphasis on hematopoietic cell-based therapy for the underlying HIV infection.

show abstract

Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients

Abstract: Key Points Rituximab use is associated with significant improvement in all outcomes for patients with HIV-associated CD20-positive lymphomas. Infusional EPOCH chemotherapy is associated with better overall survival in patients with AIDS-related diffuse large B-cell lymphoma (DLBCL).

Cited by 165 publications

References 43 publications

The biology and treatment of plasmablastic lymphoma

The biology and treatment of plasmablastic lymphoma

A new prognostic score for AIDS-related lymphomas in the rituximab-era

HIV-associated non-Hodgkin lymphoma: viral origins and therapeutic options

Contact Info

Product

Resources

About